Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMITVHM)

• Drug Name: NG-641 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMITVHM

Molecule-Related Drug Atlas

Drug(s) Targeting C-X-C motif chemokine 10 (CXCL10)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BMS-936557	DMUTS1W	Immune System disease	4A01-4B41	Phase 2	[3]
NI-0801	DMRQUH4	Autoimmune diabetes	5A10	Phase 2	[4]
MDX-1100	DM0EZWI	Crohn disease	DD70	Phase 2	[5]
Anti-IP10	DMVRNAO	Crohn disease	DD70	Phase 2	[3]
JT02	DMXTKCR	Inflammatory bowel disease	DD72	Phase 2	[6]
N-Methylleucine	DM9AGCV	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Interferon alpha (IFNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Interferon alfa-n3	DMTZNQ9	Human immunodeficiency virus infection	1C62	Approved	[8]
Alfaferone	DMCKPUR	Hairy cell leukaemia	2A82.2	Approved	[9]
P1101	DM5DRMY	Polycythemia vera	2A20.4	Phase 3	[10]
Human interferon alpha oral	DMKQ3MC	Hepatitis C virus infection	1E51.1	Phase 2	[11]
IFN-alpha	DM4H8EZ	Hepatitis C virus infection	1E51.1	Phase 2	[12]
Rontalizumab	DMBJN19	Systemic lupus erythematosus	4A40.0	Phase 2	[13]
Interferon-alpha lozenge	DM8YF01	Behcet disease	4A62	Phase 2	[14]
IFN alpha kinoid	DMLEVFW	Human immunodeficiency virus infection	1C62	Phase 1/2	[15]
AGS-009	DMU21JF	Systemic lupus erythematosus	4A40.0	Phase 1	[16]
Ad-IFN-alpha	DMM45P9	Bladder cancer	2C94	Phase 1	[17]

Drug(s) Targeting Prolyl endopeptidase FAP (FAP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Talabostat	DM1IZ5D	Constitutional neutropenia	4B00.0	Phase 3	[18]
BIBH 1	DMHYZEK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[19]
Sibrotuzumab	DMT4UC1	Metastatic colorectal cancer	2B91	Phase 2	[19]
AMG 506	DMG64PE	Solid tumour/cancer	2A00-2F9Z	Phase 1	[20]
RG7461	DM5OTGR	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]
PT630	DM9SY8E	Colon cancer	2B90.Z	Preclinical	[22]
FAP5-DM1	DMYFVZ3	Solid tumour/cancer	2A00-2F9Z	Preclinical	[23]
ARI-3099	DMIMD0T	Discovery agent	N.A.	Investigative	[24]
MIP-1231	DM2IGD1	Solid tumour/cancer	2A00-2F9Z	Investigative	[25]
FE-999040	DM3UCWM	Solid tumour/cancer	2A00-2F9Z	Investigative	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C motif chemokine 10 (CXCL10)	TTQOVYA	CXL10_HUMAN	Not Available	[2]
C-X-C motif chemokine 9 (CXCL9)	TTWE5PB	CXCL9_HUMAN	Not Available	[2]
Interferon alpha (IFNA)	TT95SOA	NOUNIPROTAC	Not Available	[2]
Prolyl endopeptidase FAP (FAP)	TTGPQ0F	SEPR_HUMAN	Not Available	[2]

References

• [1] ClinicalTrials.gov (NCT04053283) First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
• [3] Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. Gut. 2014 Mar;63(3):442-50.
• [4] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029267)
• [5] A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2012 Jun;64(6):1730-9.
• [6] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [7] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [8] Clinical pipeline report, company report or official report of Hemispherx Biopharma.
• [9] Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
• [10] Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
• [11] Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
• [12] WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
• [13] Clinical pipeline report, company report or official report of Genentech (2011).
• [14] Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
• [15] Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
• [16] Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
• [17] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
• [18] Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther. 2007 Nov;6(11):1691-9.
• [19] A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.
• [20] Clinical pipeline report, company report or official report of Amgen.
• [21] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [22] Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest. 2009 Dec;119(12):3613-25.
• [23] Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res. 2008 Jul 15;14(14):4584-92.
• [24] Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase. J Med Chem. 2013 May 9;56(9):3467-77.
• [25] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2365).